RA
CRBU icon

Royce & Associates’s Caribou Biosciences CRBU Stock Holding History

Royce & Associates’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-142,912
Closed -$280K – 849
2024
Q3 		$280K Hold
142,912
– – ﹤0.01% 823
2024
Q2 		$234K Sell
142,912
-116,016
-45% -$371K ﹤0.01% 836
2024
Q1 		$1.33M Buy
258,928
+5,826
+2% +$35.9K 0.01% 692
2023
Q4 		$1.45M Buy
253,102
+228,787
+941% +$1.13M 0.01% 693
2023
Q3 		$116K Buy
24,315
+9,615
+65% +$59.7K ﹤0.01% 889
2023
Q2 		$62.5K Hold
14,700
– – ﹤0.01% 905
2023
Q1 		$78.1K Buy
14,700
+4,100
+39% +$25.5K ﹤0.01% 902
2022
Q4 		$66.6K Buy
+10,600
New +$94.3K ﹤0.01% 898
2022
Q1 		– Sell
-12,900
Closed -$195K – 969
2021
Q4 		$195K Buy
+12,900
New +$251K ﹤0.01% 947

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's CRBU Position: Q4 2024 in Review

Royce & Associates sold out of Caribou Biosciences (CRBU) in Q4 2024, closing a stake of 142,912 shares — an estimated $280K sold.

Royce & Associates first reported a position in CRBU in Q4 2021 and held it in 9 quarters. The position peaked at $1.45M in Q4 2023. 133 funds tracked by Wall St. Rank hold CRBU as of Q4 2024.

  • Royce & Associates reported no remaining Caribou Biosciences position as of Q4 2024 after selling out during the quarter.
  • Royce & Associates sold 142,912 Caribou Biosciences shares in Q4 2024, an estimated $280K.
  • Royce & Associates first reported a position in Caribou Biosciences in Q4 2021 and held it in 9 quarters.
  • Royce & Associates's Caribou Biosciences position peaked at $1.45M in Q4 2023.
  • 133 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2024.

Based on Royce & Associates's 13F filing for Q4 2024, filed 10 Feb 2025.